Login to Your Account



ADC Therapeutics Gets $50M for Antibody-Drug Conjugates

By Cormac Sheridan
Staff Writer

Wednesday, March 28, 2012
Start-up firm ADC Therapeutics Sarl has secured funding commitments of up to $50 million to take forward 10 antibody-drug conjugate programs in oncology, based on conjugate and linker chemistry developed by London-based Spirogen Ltd.

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription